Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Elan Obtains Approval for Botulinum Toxin B in US
January 15, 2001
- SBS Transfers Tagamet to Sumitomo
January 15, 2001
- NHI Medical Costs Map Not Reflecting Reality: JMARI
January 15, 2001
- SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
- Sankyo to Codevelop Oral Antithrombotic with Lilly
January 1, 2001
- Long-term Administration of PPI Included in Insurance Coverage
January 1, 2001
- Aiming at Sales of ¥350 Bil. to ¥400 Bil. in 2005: Mr Bootes of Pfizer
January 1, 2001
- Mitsubishi-Tokyo Licenses Antiviral Agent MCC-478 to Eli Lilly
January 1, 2001
- Third Parties to Be Allowed to Provide Sperm or Ova for Infertile Couples
January 1, 2001
- Taisho Licenses CRF Receptor Antagonist to Janssen
January 1, 2001
- Serious Skin Disorders Caused by Drugs Reported: PMSB
January 1, 2001
- BMS Creates Bristol Pharmaceuticals, Spliting Off Its Pharm. Div.
January 1, 2001
- Promotion of Genomic Research Recommended by Deregulation Panel
January 1, 2001
- BASF Sells Pharma Business to Abbott
January 1, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
January 1, 2001
- Takepron Approved for Maintenance Therapy of Recurrent Reflux Esophagitis
January 1, 2001
- Business of Major Drugstore Chain Operators Continues to Expand
January 1, 2001
- JPMA to Work More Closely with Patients' Organizations
January 1, 2001
- Matsumotokiyoshi: Consolidated Half-year Sales Reach ¥115 Bil.
January 1, 2001
- Health Minister Stresses Need for Government to Support Genomic Research: 1st JPMA Forum
January 1, 2001
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…